Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Google Secures Pentagon AI Deal for Classified Projects 
WARREN, N.J., Feb. 03, 2016 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will participate in LEERINK Partners 5th Annual Global Healthcare Conference.
Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will take questions during a fireside chat at 10:40 am ET on Wednesday, February 10, 2016.
A live webcast may be accessed under the investor tab at www.bellerophon.com. An archive of the presentation will be available following the presentation.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company is currently developing two product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials shortly and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. The Company is also planning to start testing the benefits of INOpulse for patients suffering from pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) for which results are anticipated by the end of 2016. For more information, please visit www.bellerophon.com.
Contact At Bellerophon: Amy Edmonds, Vice President Head of Clinical Operations & Administration (908) 574-4765 At Rx Communications Group: Melody Carey (917) 322-2571 [email protected]
